Who
Mark A. Goldsmith
Director and Officer
Company insider
Files Form 4 as: Director and Officer, Revolution Medicines; Director and 10% owner, Constellation Pharmaceuticals.
In numbers
- Trades disclosed
- 338
- Buys
- 0
- Sells
- 61
- Bought
- $0
- Sold
- $127.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 19 Jul 2018
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $42K213 at $195.01 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $2.7M13,775 at $199.30 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $42K213 at $195.01 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $2.7M13,775 at $199.30 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $378K80,000 at $4.73 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $283K1,351 at $209.28 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $29K136 at $210.40 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $52K245 at $211.47 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $27K127 at $212.06 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $37K177 at $207.25 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $195K937 at $208.36 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $294K1,405 at $209.27 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $27K126 at $210.40 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $48K229 at $211.46 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $27K126 at $212.06 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $1.1M5,128 at $207.23 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $5.2M24,917 at $208.37 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $7.5M35,938 at $209.26 | filing |
News
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026RVMD · manilatimes.net · 23 Oct 2026Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)RVMD · themarketsdaily.com · 22 Oct 20263,946 Shares of Revolution Medicines, Inc. $RVMD Acquired by Vontobel Holding Ltd.RVMD · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Mark A. Goldsmith; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.